Thomas Wiggans

Thomas G.
Wiggans is the founder of Dermira, Inc., founded in 2010.
Current jobs include Chairman at The Biotechnology Institute, Executive Chairman at Follica, Inc. since 2021, Executive Chairman at Jasper Therapeutics, Inc. starting 2026, Director at Forma Therapeutics, Inc., Director at The Hoover Institution, Independent Director at Pacira Biosciences, Inc. starting 2026, Trustee at Kansas University Endowment Association, Trustee at Kansas Association of Defense Counsel, and Trustee at Wiggans Living Trust.
Former jobs include Chairman & Chief Executive Officer at Connetics Corp.
in 2006, Chairman & Chief Executive Officer at Peplin, Inc. from 2008 to 2009, Chairman & Chief Executive Officer at Pardes Biosciences, Inc. from 2022 to 2023, Chairman at Excaliard Pharmaceuticals, Inc. from 2010 to 2011, Chairman at Annexon, Inc. from 2021 to 2026, Independent Director at Onyx Pharmaceuticals, Inc. from 2011 to 2013, Director at Abgenix, Inc., Independent Director at Sangamo Therapeutics, Inc. from 2011 to 2012, Director at Corthera, Inc., Director at Tercica, Inc. from 2005 to 2006, Independent Director at Somaxon Pharmaceuticals, Inc. from 2011 to 2012, Independent Director at Forma Therapeutics Holdings, Inc. from 2020 to 2022, Director at Victory Pharma, Inc., Director at Neothetics, Inc. from 2011 to 2014, Independent Director at CymaBay Therapeutics, Inc. from 2021 to 2024, Director at Biotechnology Innovation Organization, Principal at Eli Lilly & Co., President & Chief Operating Officer at CytoTherapuetics, Inc. from 1992 to 1994, and President-US Pharmaceutical Operations at Ares-Serono Group from 1980 to 1992.
Education includes an MBA degree from Southern Methodist University conferred in 1976 and an undergraduate degree from the University of Kansas conferred in 1975.